Available Technology

A3 Adenosine Receptor Agonists for Treating Chronic Neuropathic Pain

The current invention describes selective A3 Adenosine Receptor agonists and their in vivo activity reducing or preventing development of chronic neuropathic pain in an animal model. Chronic neuropathic pain (NP) is a widespread condition that is often associated with diabetes, cancer chemotherapy, injury as well as a variety of other diseases. Current therapies for NP are not always effective and patients suffer from serious side effects, such as liver toxicity and addiction. Opioids, while effective against acute pain, are not the first line of treatment for chronic NP because of their addictive qualities and low efficacy. Thus, there is an unmet need for chronic neuropathic pain treatment that operates on a different mechanism.
Patent Abstract: 
The current invention describes selective A3 Adenosine Receptor agonists and their in vivo activity reducing or preventing development of chronic neuropathic pain in an animal model. Chronic neuropathic pain (NP) is a widespread condition that is often associated with diabetes, cancer chemotherapy, injury as well as a variety of other diseases. Current therapies for NP are not always effective and patients suffer from serious side effects, such as liver toxicity and addiction. Opioids, while effective against acute pain, are not the first line of treatment for chronic NP because of their addictive qualities and low efficacy. Thus, there is an unmet need for chronic neuropathic pain treatment that operates on a different mechanism.
Benefits 
The compounds are consistently highly selective and have smaller molecular weight, thus greater oral bioavailability is possible.
applications 
Inventors: 
Kenneth Jacobson
Patent Number: 
PCT/US2014/066609 US Application No. 15/039,778 US
Internal Laboratory Ref #: 
E-742-2013/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin